Century Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Century Therapeutics

30/07/2025 13:38

Century Therapeutics Inc IPSC.OQ IPSC.O is expected to  show a fall in quarterly revenue when it reports  results on August 1 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Century Therapeutics Inc is for a loss of 38 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Century Therapeutics Inc is $5.00, about 88.3% above its last closing price of $0.58

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
0.05
0.06
0.89
Beat
1,518.2
Dec. 31 2025
-0.42
-0.43
Missed
-1.9
Sep. 30 2024
-0.44
-0.45
-0.37
Beat
17.4​
Jun. 30 2024
-0.47
-0.46
-0.38
Beat
17.6
​​Mar. 31 2024
-0.52
-0.50
-0.45
Beat
10.4
Dec. 31 2023
-0.46
-0.55
-0.65
Missed
-17.3​
Sep. 30 2023
-0.52
-0.51
-0.55
Missed
-7.3
Jun. 30 2023
-0.55
-0.54
-0.56
Missed
-2.9

This summary was machine generated July 30 at 12:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)